Be sure to visit our special section on the 11th
Conference on Retroviruses and Opportunistic Infections (CROI
2004), which ended on Feb. 11. Among the latest articles posted
are a review of recent research on neuropathy and an examination
of a unique new HIV treatment strategy that may help doctors pinpoint
the best HAART regimens for their patients. Our searchable conference
coverage is also sorted by topic, so you can head straight to the
research that interests you the most!
As always, please write if you have any thoughts or questions. Regards,
Goldman, Editorial Director, The Body
TRACKING & PREVENTION
of Every Three HIV Infections Occurs Through Heterosexual Sex
More than a third of all new HIV infections reported in the U.S.
from 1999 to 2002 were transmitted through heterosexual sex, and
most of those heterosexual infections occurred among African Americans
(74%) and women (64%), according to new figures from the Centers
for Disease Control.
Officials Begin Using the Web as an HIV Prevention Tool
The Internet presents new challenges and opportunities for curbing
the spread of HIV and other sexually transmitted diseases (STDs).
With so many people using the Internet to meet sex partners, can
public health departments also use the Internet to prevent and control
STDs? The outcomes of some initial attempts bode well.
People Make Up 50% of STD-Infected Population in U.S.
Americans between the ages of 15 and 24 account for half of
all people infected with sexually transmitted diseases (STDs) in
the U.S., according to a pair of U.S. studies. Advocates of comprehensive
sex education point to the findings as a sign that teaching abstinence
just isn't enough to prevent the spread of HIV and other STDs.
PROBLEMS FOR HIVERS
Can Prevent, Lessen Impact of Peripheral Neuropathy
remains one of the most painful disorders for people living with
HIV. Fortunately, the use of HAART has been associated with both
protection from and reversal of neuropathy, reports Dr. Keith Henry
from CROI 2004.
Your Cholesterol, for Your Heart's Sake
Your blood cholesterol level has a lot to do with your chances
of getting heart disease -- whether you have HIV or not -- so it's
important to keep an eye on it. Here's a simple, thorough explanation
of which cholesterols are good and which can lead to trouble. This
article includes surveys that both men and women can use to calculate
your risk of having a heart attack.
AT THE BODY
You Can Use: Our New Home for Interactive HIV-Related Resources
All of The Body's interactive resources now live in one place:
our newly launched Tools You Can Use Page. Among many other useful
items, this page features a handy AIDS organization search, our
unique HIV risk assessment quiz and the debut of our monthly online
on Immune-Based HIV Therapies
Although research into immune-based therapies (IBTs) for HIV
has been going on as long as antiretroviral research, there is still
not one IBT on the market. What gives? In this update, Richard Jeffreys
explains why IBTs are taking so long, and examines some therapies
currently in development.
Drug Interactions: A Detailed Review
Looking for in-depth information about interactions between
HIV medications? This detailed clinical reference from HEPP Report
provides an overview of the key drug-drug interactions associated
with HIV antiretrovirals.
Also take a look at The Body's library
of articles on drug-drug interactions. It includes explanations,
overviews and some of the latest research on the subject.
to Find the Right Complementary HIV Therapist
How can you determine whether the alternative medicine specialist
you're going to is legit or a quack? What can you do to ensure the
highest quality of complementary health care? This list of frequently
asked questions from National Center for Complementary and Alternative
Medicine can help you find the answers.
Strategy Tries to Turn Failing HAART Into Better HAART
Stopping just one drug in a failing HAART regimen may help doctors
identify specific combinations of drugs that are still effective
against HIV, even in people who have already tried many different
HAART combinations. Gerald Pierone Jr., M.D., reports on this small
but interesting study presented at CROI 2004.
AIDS POLICY AND ACTIVISM
Yourself a Voice on HIV Treatment Research: Join a CAB!
Finding meaningful volunteer work is always a challenge. One
excellent opportunity that often gets overlooked is a volunteer
position on a Community Advisory Board (CAB). David Mariner explains
what it means to be on a CAB.
OUTSIDE THE U.S.
Administration Announces Details of Global AIDS Plan
Nine months after signing the bill into law, the Bush Administration
has released the details of its five-year, $15 billion plan to fight
AIDS in the developing world. Randall L. Tobias, the appointed coordinator
of the U.S.'s global AIDS efforts, talked with the media about the
plan at a press conference earlier this week.
Want the full details of the U.S. global AIDS initiative? The government's
99-page report on the plan (PDF, 1.9MB) provides all the facts.
The newly released details of President Bush's five-year, $15 billion
global AIDS initiative have received a less-than-warm
reception from AIDS advocates. This article from the Inter Press
Service has more details on activists' reaction to the plan.
Among the first grants doled out in President Bush's global AIDS
initiative is $107 million for Harvard's School of Public Health,
which the school plans to use to provide
antiretrovirals to an additional 75,000 people in Nigeria, Tanzania,
and Botswana, the Boston Globe reports.
AIDS Epidemic Threatens Western Europe, Warns UN
With Eastern Europe and Central Asia home to some of the highest
rates of HIV infection in the world, the countries of the European
Union are emplored to take action.
Article from the Independent, February 24, 2004
and Hepatitis Coinfection
Two new studies suggest that the most effective treatment for people
infected with both HIV and hepatitis C is a regimen consisting of
peginterferon alfa-2a (Pegasys) and ribavirin, according to this
CROI 2004 coverage from HIV InSite, February 23, 2004
Over 50 at Increased Risk of Cognitive Impairment, Even With HAART
People with HIV who are over the age of 50 are more likely to experience
diminishing brain function than HIV-positive people under 40, whether
or not they are taking HAART, according to a recent U.S. study.
Article from aidsmap.com, February 19, 2004
and HIV Drug Resistance
"Near-perfect" adherence to a powerful HAART regimen appears
to be the best way to avoid developing drug-resistant HIV, this
research review concludes.
Article from The Hopkins HIV Report, January 2004